---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341239"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-08-10T11:19:57+00:00"
generated_at: "2026-08-10T11:25:06.754733+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire Apogee for $135.11/share (~$10.9B); Q2 results reported

## Summary
- AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value; expected close Q3 2026.
- Phase 2 APEX Part B met endpoints: 65.9% EASI-75 (41.9% placebo-adjusted) with mid-dose zumilokibart.
- Cash $1.3B at June 30, 2026; Q2 net loss $85.9M vs $66.1M year ago.
- Blackstone financing collaboration up to $1.3B non-dilutive for zumilokibart development.
- Phase 3 initiation for zumilokibart in atopic dermatitis planned this year; EoE and asthma trials set.

## SEC filing metadata
- accession: 0001193125-26-341239
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-08-10T11:19:57+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/0001193125-26-341239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/apge-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341239
- JSON: https://secwatch.observer/filing/0001193125-26-341239.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.